Disease outbreak boosts Bavarian stock

Bavarian Nordic’s stock has become the top performer on the Danish C25 stock index on Wednesday, following the company’s announcement of seeking approval to market its vaccine against the chikungunya virus in Europe. While this was already anticipated, a surge in the stock value is likely due to reports from multiple media outlets, including the BBC, about the discovery of a new strain of monkeypox spreading in the eastern Democratic Republic of Congo. Bavarian Nordic holds the patent for Jynneos, the only approved monkeypox vaccine. Previous outbreaks in Africa have led to substantial orders from countries preparing for potential outbreaks.